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Background: Epidemiological studies have shown considerable heritability of blood pressure, thus suggesting a
role for genetic factors. Previous studies have shown an association of a single nucleotide polymorphism rs5068 in
the NPPA locus gene with higher levels of circulating atrial natriuretic peptide as well as with lower intra individual
blood pressure, but up to date, no association between rs5068 and cardiac organ damage, i.e. left ventricular
hypertrophy, has been accounted for in humans. We sought to explore if rs5068 is associated with left ventricular
hypertrophy as measured by echocardiographic examination in a non-diabetic population.
Methods: 968 non-diabetic individuals from the Malmö Preventive Project (mean age 67 years; 31% women) were
genotyped and examined with echocardiography. Logistic regression was used to adjust for covariates.
Results: The minor allele of rs5068 was associated with decreased prevalence of left ventricular hypertrophy
(p = 0.021) after adjustment for sex and age. In the multivariate logistic analysis including; age, sex, systolic blood
pressure, antihypertensive and/or cardioprotective treatment, body mass index and fasting plasma glucose, the
association of rs5068 with left ventricular hypertrophy was, as expected, attenuated (p = 0.061).
Conclusion: In a non-diabetic population, the minor allele of rs5068 was associated with lower left ventricular mass.
These findings suggest that rs5068, or genetic variants in linkage disequilibrium, might affect susceptibility to left
ventricular hypertrophy and support the possible protective role of natriuretic peptides.Background
Atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) are secreted from cardiomyocytes in response
to cardiac wall stress and have important roles in the regu-
lation of extracellular fluid volumes and blood pressure
(BP) [1-3]. Animal studies have shown that over expres-
sion of natriuretic peptide genes is associated with low BP,
whereas under expression is associated with high BP and
left ventricular hypertrophy (LVH) [4,5], and studies on* Correspondence: amra.jujic@mah.se
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reproduction in any medium, provided the ormice with inactivated type A natriuretic peptide receptors
(NPRA) have even shown hypertrophic growth of the
heart independently of BP levels [6]. The suppressive effect
of ANP on hypertrophy has also been demonstrated in
cardiomyocytes in culture [7] and a recent study showed
salt-sensitive hypertension in natriuretic peptide precursor
A (NPPA) knockout mice, demonstrating that genetically
reduced production of ANP can lead to salt-sensitive hyper-
tension [8]. Evidence of substantial heritability of plasma
natriuretic peptide (NP) levels has also been accounted for
[9] and low circulating NP levels have been associated with
obesity [10] and new onset diabetes [11], which may con-
tribute to their predisposition to hypertension.
The NPPA and natriuretic peptide precursor B (NPPB)
genes lie in tandem 9.7 kb apart on chromosome 1.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.







N 968 820 148
Sex (% women) 30.5 30.6 29.7
Age (years) 67.1 (±5.7) 66.7 (±5.7) 69.4 (±5.2)
Systolic BP (mmHg) 146.0 (±19.3) 145.1 (±19.0) 150.8 (±20.2)





Hypertension (%) 74.5 71.5 91.1
BMI 27.3 (±3.8) 26.9 (±3.4) 29.8 (±4.8)
FPG (mmol/l)* 5.8 [0.9] 5.8 [1.0] 6.1 [1.0]
Data are expressed as mean (±SD) or median [interquartile range (IQR)]*.
BP blood pressure, BMI body mass index, FPG fasting plasma glucose.
Jujić et al. BMC Medical Genetics 2013, 14:64 Page 2 of 6
http://www.biomedcentral.com/1471-2350/14/64Associations between common variations (rs5068, rs198358
and rs632793) in NPPA-NPPB locus genes and higher
levels of circulating ANP were found in a recent study as
well as association with lower interindividual BP, with the
strongest effect for rs5068 [12], findings that have been rep-
licated in larger cohorts [13]. The minor allele of rs5068
has also been associated with favorable cardiometabolic
profile [14], and there is evidence for an important protect-
ive role of the natriuretic peptides in individuals with cor-
onary artery disease [15], but surprisingly no association
with echocardiographic evidence of cardiac organ damage,
such as LVH, for this particular SNP. However, since LVH
is well known to be overrepresented in patients with dia-
betes mellitus [11,16-19] the inclusion of subjects with dia-
betes, 17% and 15% respectively) might explain the lack of
association of rs5068 and LVH [14,15].
Here we tested the hypothesis that rs5068 suppressively




Between 1974–1992, birth cohorts (men born in 1921,
1926–1942, 1944, 1946 and 1948–9; women born in
1926, 1928, 1930–6, 1938, 1941–2 and 1949) of inhabi-
tants in Malmö, Sweden, were invited to participate in a
large cohort study The Malmö Preventive Project (MPP)
with a total of 33,346 individuals attending (67% men, at-
tendance rate 71%, mean age 46 ± 7 years). Re-examination
of 18,240 surviving MPP participants, the MPP-Re-examin-
ation Study (MPP-RES) was conducted during 2002–2006
(63% men, 72% attendance rate, mean age 69 ± 6 years). All
participants answered a self-administered questionnaire on
lifestyle and medical history. Height and weight were
measured in light in-door clothing, waist circumference
was measured and body mass index (BMI) was calculated
(kg/m2). Patient BP and pulse rate were measured twice in
the supine position after 10 minutes of rest and blood sam-
ples were drawn after an overnight fast. In a sample of
1,792 participants, echocardiography (UCG) and electrocar-
diography (ECG) recordings were carried out. These sub-
jects were randomly selected from groups defined by
glucometabolic status: normal fasting plasma glucose (FPG)
(≤6.0 mmol/l); impaired FPG (IFG); new-onset type 2
diabetes mellitus; and prevalent diabetes mellitus; with
oversampling in groups of subjects with glucometabolic
disturbances to ensure sufficient numbers of subjects stud-
ied from each group. A full description of this study popu-
lation has been presented elsewhere [20]. Subjects with
prevalent diabetes mellitus type 1 or 2 (n = 677) were ex-
cluded from our analysis due to previously shown overrep-
resentation of diastolic dysfunction and LVH within the
diabetic phenotype [11,16,17], resulting in a total of 1,115
subjects. Of these 1,115 subjects, 147 had missing values ofone or more covariates used in the multiple regression ana-
lysis, resulting in 968 eligible subjects.
All participants signed a written informed consent form
before entering the MPP-RES. The study was approved by
The Ethics committee at Lund University, Sweden.
Echocardiography
Conventional echocardiograms were obtained with an
Acuson Sequoia, Mountain View, CA, USA (3V2c trans-
ducer) or Sonos 5500 Philips, Andover, MA, USA (S3
transducer). All echocardiograms were carried out by expe-
rienced sonographers. Internal left ventricular dimensions
were evaluated from parasternal long axis view according
to the recommendations of the European Association of
Echocardiography. Measurements of wall thickness were
obtained in two-dimensional end-diastolic parasternal long
axis view, where left ventricular mass (LVM) was calculated
during a single heart cycle if recordings were homoge-
neous, otherwise a mean of three to five measurement of
different heart cycles was used. LVM was calculated
according to clinical standards and indexed for height2.7 to
minimize the effect of obesity on LVM calculations [21].
Two sonographers analysed images independently
from a random sub-sample of subject to test inter- and
intra-observer variability which was 13.0% and 10.5% for
intraventricular end-diastolic septum diameter, and 4.1%
and 3.3% for left ventricular end-diastolic diameter. Both
sonographers were experienced and blinded to clinical
data. All analyses were performed offline using Xcelera
software (Philips).
Genotyping
Variants in NPPA-NPPB locus genes were analysed by
direct genotyping as described previously using TaqMan
(Applied Biosystems) with primers and conditions as
recommended by the manufacturer [12]. Twenty five
Table 2 Genotype frequencies of rs5068
Total sample Subjects without LVH Subjects with LVH
Frequency (n) Percent (%) Frequency (n) Percent (%) Frequency (n) Percent (%)
AA 847 87.5 710 86.6 137 92.6
AG 117 12.1 106 12.9 11 7.4
GG 4 0.4 4 0.5 0 0
Total 968 100 820 100 148 100
Genotype frequencies of rs5068 in total sample, subjects without diabetes and subjects with diabetes. Major allele represented by A, minor allele represented by G.
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discrepancies.Laboratory assays
All FPG analyses were performed by Department of
Clinical Chemistry, Malmö University Hospital which is
attached to a national standardization and quality con-
trol system (Beckman Coulter LX20, Beckman Coulter
Inc, Brea, USA).
Other definitions
If LVM was >51 g/m2.7, LVH was considered prevalent
[21,22]. Antihypertensive and/or cardioprotective treat-
ment was defined as use of one or more of the following;
β-receptor blockers, calcium channel blockers, lipid lower-
ing drugs, angiotensin converting enzyme inhibitors, long-
acting nitrates, angiotensin receptor blockers, digitalis and
diuretics. Prevalent hypertension was defined as the
presence of either one or more of the following; systolic
BP (SBP) > 140 mmHg and/or diastolic BP >90 mmHg
and/or antihypertensive and/or treatment by the time of
the third visit. Diabetes was defined as previously
known diabetes mellitus type 1 or 2, whereas new-onset
diabetes mellitus type 2 was defined by either two separ-
ate measurements of FPG ≥7.0 mmol/l, or one single
measurement of ≥11.1 mmol/l.Statistical analysis
Continuous variables were expressed as mean ± stand-
ard deviation (SD). FPG was not normally distributed
and was log transformed prior to analysis. LVM was
modeled as the dependent variable in linear regressionTable 3 Left ventricular mass index (g/m2.7)
LVM index (g/m2.7) n Min Max Mean SE
Total population 968 18.96 99.31 40.44 11.28
Subjects without LVH 820 18.96 50.97 36.86 7.13
Subjects with LVH 148 51.00 99.31 60.21 9.36
Values are beta-coefficients (standard errors).
LVM index for the total population, for patients with and patients without LVH.and the presence of LVH via logistic regression with
rs5068 genotype as independent variable using additive
models with the minor allele (G) coded. All modeling
was performed in models adjusted for age and sex
(model 1) and for age, sex, BMI, SBP, antihypertensive
and/or cardioprotective treatment, and FPG (model 2).
A two-tailed significance level of p < 0.05 was consid-
ered statistically significant. All calculations were done
in SPSS 19.0 (SPSS Inc, Illinois, USA).
Results
Baseline characteristics for the entire non diabetic popula-
tion and subgroup characteristics (subjects without, and
subjects with LVH) are presented in Table 1. The mean
age of participants was 67.1 years and 30.5% of subjects
were female. Subjects with LVH were older (p < 0.001),
with higher BMI (p < 0.001), SBP (p = 0.001) and higher
prevalence of hypertension (p < 0.001) compared to sub-
jects without LVH. Genotype frequencies of rs5068 are
presented in Table 2. LVM index for the total population,
subjects without LVH and subjects with LVH is presented
in Table 3.
In logistic regression analysis, the rs5068 minor allele
was significantly associated with lower prevalence of
LVH (p = 0.021) (Table 4). However, after adjustment
according to model 2 (age, sex, SBP, antihypertensive
and/or cardioprotective treatment, BMI and logFPG)
this correlation was attenuated (p = 0.061) (Table 5). Re-
sults for Hosmer-Lemeshow goodness of fit test as well
as sensitivity, specificity and percent of overall correct
for model 2 are presented in Table 6.
In linear regression analysis, the minor allele of
rs5068 was significantly associated with decreased LVM
indexed for height2.7 after adjustment according toTable 4 Association of rs5068 with LVH in a non diabetic
population adjusted for age and gender*
B SE Wald P-value OR (95% CI)
Gender −0.331 0.203 0.656 0.103 0.72 (0.48-1.07)
Age 0.095 0.017 31.205 <0.001 1.10 (1.06-1.14)
rs5068 −0.757 0.328 5.311 0.021 0.47 (0.25-0.89)
*Model 1: Age and sex adjusted.
Values are odds ratios (95% confidence intervals) for prevalent LVH. SE values
are standard errors. B values are unstandardized regression coefficients.
Table 5 Association of rs5068 with LVH in a non diabetic
population in a fully adjusted model*
B SE Wald p-value OR (95% CI)
Gender −0.460 0.225 4.165 0.041 0.63 (0.41-0.98)
Age 0.101 0.019 29.714 <0.001 1.12 (1.07-1.15)
rs5068 −0.630 0.337 3.504 0.061 0.53 (0.28-1.03)
BP 0.010 0.005 4.590 0.032 1.01 (1.00-1.02)
logFPG 0.177 0.867 0.042 0.838 1.19 (0.22-6.53)
AHT 0.525 0.202 6.789 0.009 1.69 (1.14-2.51)
BMI 0.191 0.027 48.988 <0.001 1.21 (1.15-1.28)
*Model 2: Age, sex, BP, AHT, logFPG and BMI adjusted.
Values are odds ratios (95% confidence intervals) for prevalent LVH. SE values
are standard errors. B values are unstandardized regression coefficients.
Table 7 Association of rs5068 with LVM Indexed for
Height2.7 in a non Diabetic Population adjusted for age
and sex*
B SE Beta p-value Adjusted
R Square
F
Age 0.567 0.064 0.287 <0.001
rs5068 −2.060 1.006 −0.063 0.041
Gender −3.126 0.794 −0.127 <0.001
Full equation <0.001 0.076 27.645
*Model 1. Adjusted for age and sex.
SE values are standard errors. Beta values are standardized regression
coefficients. B are unstandarized coefficients.
Table 8 Association of rs5068 with LVM Indexed for
Height2.7 in a non diabetic population in a fully adjusted
model*
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variate adjustment according to model 2 this association
was no longer significant (p = 0.165) (Table 8). Seven
point six percent of the variation in the response vari-
able can be explained by the explanatory variables.
Hardy Weinberg equilibrium significance analysis did
not show any significant deviation (p-value = 0.117).
Discussion
The key finding of our study is that the minor allele of
rs5068 is associated with lower LVM as well as lower
prevalence of LVH in a non-diabetic population after ad-
justments for age and sex.
These associations were attenuated in the multivariate
analysis in which SBP and antihypertensive and/or
cardioprotective treatment were included. One possible
explanation for this could be that the observed associ-
ation between the minor allele of rs5068 and lower like-
lihood of LVH is explained by lower BP mediated by the
same polymorphism [12]. On the other hand, the attenu-
ation of the association between rs5068 and LVH after
full adjustment was rather modest, suggesting that the
ANP elevating effects of the rs5068 G-allele also may
contribute with BP independent effects on LVH. We ac-
knowledge that the effect size is small, as commonly the
case is in polygenic situations. However, the effect sizeTable 6 Hosmer-Lemeshow goodness of fit test,
sensitivity, specificity and percent of overall correct for
association of rs5068 and LVH in a fully adjusted model*
Number of observations 968
Number of groups 10
Hosmer-Lemeshow chi2(8) 10.42




*Model 2: Age, sex, BP, AHT, logFPG and BMI adjusted.for most variants is small and a single SNP can only ex-
plain a small proportion of the expected heritability.
In contrast to the results of Cannone and co-workers
[14], but also Ellis and co-workers [15], we were able to
show a significant association between the minor allele of
rs5068 and reduced prevalence of LVH, which can be
explained by our exclusion of subjects with diabetes. LVH
is heavily overrepresented in patients with diabetes [19,23]
and the existence of a specific diabetic cardiomyopathy
has been an ongoing debate over the past decades [24]. It
is likely to presume that the “harmful” diabetic phenotype
overrides the cardioprotective and/or the blood pressure
lowering effects of the minor allele of rs5068. Also, in com-
parison of clinical studies of LVH, adequate correction is of
critical importance, since both body habitus and size are as-
sociated with LV mass and dimensions. Normalization of
LV mass is still a subject for debate, since different criteria
for body size adjustment result in different prevalence of
patients with LVH. The body surface area correction has
been shown to underestimate LVM in the upper range of
body surface area distribution, and a height-based adjust-
ment has been proposed to correct for obesity. The most
accurate estimation of LVH appears to be derived from
indexing for height2.7, where 51 g/m2.7 appears to be aB SE Beta p-value Adjusted
R Square
F
BP 0.053 0.017 0.090 0.002
FPG −1.323 2.937 −0.014 0.653
Age 0.537 0.060 0.272 <0.001
rs5068 −1.282 0.922 −0.039 0.165
BMI 1.033 0.089 0.347 <0.001
AHT 2.140 0.678 0.093 0.002
Gender −3.274 0.747 −0.134 <0.001
Full equation <0.001 0.228 41.754
*Model 2: Age, sex, BP, AHT, logFPG and BMI adjusted. SE values are standard
errors. Beta values are standardized regression coefficients.
Jujić et al. BMC Medical Genetics 2013, 14:64 Page 5 of 6
http://www.biomedcentral.com/1471-2350/14/64reliable cut off value to define LVH, as used in our study.
[21] As both Cannone and Ellis corrected for body surface
area, our results may not be fully comparable.
Echocardiography is the most commonly used imaging
modality in assessing LVM, left ventricular size and
performance. However, it is subjective and operator
dependent and contends with inter- and intraobserver
variability, particularly when using harmonic imaging in
assessing LVM. Even though harmonic imaging tends to
overestimate wall thickness, it has also improved delinea-
tion of the left ventricle, especially in subjects with bad
image quality [25]. All methods for quantitation of LVM
using two-dimensional imaging have been validated previ-
ously [26,27]. We sought to minimize the effects of sub-
jectivity on our data by testing if inter- and intraobserver
variability between two independent readers analysing
images was within acceptable levels.
As our sample size was relatively small, the results
warrant replication in a larger cohort.
As this is a cross-sectional study, it shares the inherent
limitations about causality and control as all cross-
sectional studies. Still, the genetic effect is not expected
to be hampered by such confounding, as the genome is
constant throughout life.
Our data was collected at a single regional centre
which limits the applicability to other populations and
allows the influence of community characteristics. On
the other hand, inter-observer bias regarding the UCG
measurement was less than would be expected in a
multi-centre study. Also, although the subjects with
congestive heart failure were overrepresented in the
original population, excluding subjects with diabetes
resulted in low number of subjects with congestive
heart failure (n = 4). In order to prove that inclusion of
those subjects does not have any impact on our data, we
performed a sensitivity analysis by excluding patients
with prevalent heart failure and received very similar
data (not shown). Hence, inclusion of patients with con-
gestive heart failure is not considered to have any im-
pact on our results.
Finally, our study results may not be generalizable to
all ancestries since the study was undertaken in mainly
individuals of Swedish descent.Conclusions
In a non-diabetic population, the minor allele of rs5068
was associated with lower LVM and lower prevalence of
LVH. Whether the association is mediated by the BP
lowering effect of rs5068 or is independent of BP is
uncertain. However, our findings suggest that rs5068 or
genetic variants in linkage disequilibrium might affect
susceptibility for LVH and support the possible protect-
ive role of NP.Competing interests
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